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Abstract
Background: Transgenic (TG) mice with overexpression of an arg120gly (R120G) missense mutation in HSPB5 display
desmin-related cardiomyopathy, which is characterized by formation of aggresomes. It is also known that progressive
mitochondrial abnormalities and apoptotic cell death occur in the hearts of R120G TG mice. The role of mitochondrial
dysfunction and apoptosis in disease progression, however, remains uncertain.
Methods and Results: Mitochondrial abnormalities and apoptotic cell death induced by overexpression of HSPB5 R120G
were analyzed in neonatal rat cardiomyocytes. Overexpression of mutant HSPB5 led to development of aggresomes with a
concomitant reduction in cell viability in the myocytes. Overexpression of mutant HSPB5 induced a reduction in the
cytochrome c level in the mitochondrial fraction and a corresponding increase in the cytoplasmic fraction in the myocytes.
Down-regulation of BCL2 and up-regulation of BAX were detected in the myocytes expressing the mutant HSPB5.
Concomitant with mitochondrial abnormality, the activation of caspase-3 and increased apoptotic cell death was observed.
Cell viability was dose-dependently recovered in myocytes overexpressing HSPB5 R120G by treatment with nicorandil a
mitochondrial ATP-sensitive potassium channel opener. Nicorandil treatment also inhibited the increase in BAX, the
decrease in BCL2, activation of caspase-3 and apoptotic cell death by mutant HSPB5. To confirm the results of the in-vitro
study, we analyzed the effect of nicorandil in HSPB5 R120G TG mice. Nicorandil treatment appeared to reduce
mitochondrial impairment and apoptotic cell death and prolonged survival in HSPB5 R120G TG mice.
Conclusions: Nicorandil may prolong survival in HSPB5 R120G TG mice by protecting against mitochondrial impairments.
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Introduction
The anti-anginal agent nicorandil is known as an opener of the
ATP-sensitive potassium (KATP) channel with a nitrate moiety
[1]. A significant amount of clinical evidence has demonstrated
that nicorandil protects the heart against ischemic injury [1],
improves the recovery of post-ischemic contractile dysfunction and
can reduce infarct size in several animal models [2]. The impact of
nicorandil in angina (IONA), a randomized and placebo-
controlled study, has shown that nicorandil reduced the incidence
of major cardiovascular events in patients with angina pectoris
[1,3]. Although it remains uncertain whether nicorandil has an
infarct-limiting effect in humans, a great deal of attention has been
attracted to molecular mechanisms by which nicorandil exerts a
cardioprotective action. Besides the beneficial hemodynamic
effects, such as increased coronary blood flow and reduced
vascular resistance, recent studies suggest that the cardioprotective
effects of nicorandil are mediated by activation of mitochondrial
ATP-sensitive potassium (mitoK(ATP)) channels in myocytes
[2,4]. Many studies suggest that the mitoK(ATP) channels are
implicated in the mechanism(s) of ischemic preconditioning (IPC),
apoptosis and mitochondrial matrix swelling [5], while it’s
physiological role, functional regulation and exact structure
remain to be determined [5].
The R120G missense mutation in heat shock protein (HSP) B5
(also known as alpha-B-crystallin) can cause desmin-related
cardiomyopathy (DRM) [6]. This disease, which is characterized
by the formation of aggregates containing HSPB5 and desmin, is a
misfolded protein-related disease that can be recapitulated in
transgenic (TG) mice by expressing the mutant HSPB5 R120G
(R120G) protein specifically in the cardiomyocytes [7]. We showed
that R120G caused perinuclear aggresome formation and that
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(amyloid oligomers) [8]. These results suggest that DRM caused by
the HSPB5 mutation is a subclass of aggresomal and amyloid-
related diseases [8]. Our previous study also suggests that cellular
toxicity induced by amyloid oligomers is associated with
mitochondrial function as well as induction of apoptotic cell death
by cytochrome c release from mitochondria [8,9]. Pharmacolog-
ical intervention such as grenylgrenylaceton (GGA), which can
enhance HSP(s) induction and can attenuate amyloid oligomer
formation, showed an effectiveness towards cardiac disease, such
as reduced cardiac function, cardiac hypertrophy, interstitial
fibrosis, and what appeared to be apoptotic cell death in mutant
R120G TG mice [8]. It is uncertain, however, whether inhibition
of the apoptotic cell death is sufficient for treatment of DRM.
In this study, we showed that nicorandil treatment could inhibit
development of mitochondrial abnormalities as well as apoptotic
cell death via a mitoK(ATP) channel opening in this model
although levels of protein aggregates and amyloid oligomers were
unchanged. Concomitant inhibition of apoptotic cell death and
blockade of alteration levels of BCL family members such as BCL2
and BAX were observed in the nicorandil-treated R120G TG
mice. These results imply that mitochondria protection as well as
inhibition of subsequent apoptotic cell death by nicorandil, a
mitoK(ATP) channel opener, may represent a new therapeutic
strategy for treating patients with DRM.
Materials and Methods
Recombinant protein
To produce a recombinant protein, His epitope-tagged wild-type
HSPB5-FLAG, HSPB5 R120G-FLAG were overexpressed in BL21
cells (Invitrogen, Carlsbad, CA, USA) using the pET system
(Novagen, Madison, WI) and purified with a Ni-NTA column
(Qiagen, Santa Clarita, CA) as described previously [10]. The
amyloid oligomer level, each recombinant protein or protein mixture
with nicorandil was incubated and blotted on a nitrocellulose
membrane and quantified as described previously [10].
Cardiomyocyte cultures and adenovirus infection
Rat neonatal cardiomyocytes were isolated using the Worthing-
ton Cardiomyocyte Isolation System (Worthington Biochemical
Corporation, Lakewood, NJ). After isolation of rat neonatal
cardiomyocytes, cells were grown on glass slides coated with a
gelatin, as described previously [8]. The cells were normally
infected at a multiplicity of infection of 10 for each virus except
where indicated. Replication-deficient recombinant adenoviruses
were made using an AdEasy system (Agilent Technologies, Palo
Alto, CA), as described previously [10,11].
Immunohistochemistry
Immunohistochemical analyses were performed as described
previously [8]. Alexa488-conjugated anti-rabbit, and Alexa568-
conjugated anti-mouse antibodies were purchased from Molecular
Probes (Eugene, OR), Anti-HSPB5 antibody (SPA-223) from
Assay Designs, Inc. (Ann Arbor, MI), and anti-cTnI antibody
(MAB1691) from Millipore (Billerica, MA). The anti-oligomer
antibody (A-11) was generated and used as described previously
[8]. The cellular viability was measured using a 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT)
assay [8]. Image J 1.386 was used to quantify the immunofluo-
rescent intensity. The results from 30–50 cells were averaged for
cohort comparison. The area stained with the oligomer antibody
was defined, and the average pixel intensity of the cardiomyocyte
was determined for comparison [8].
Isolation of mitochondrial and cytosolic fractions
Isolation of mitochondrial and cytosolic fractions was performed
as described previously [9]. Hearts were homogenized in buffer
containing 250 mM sucrose, 10 mM Tris-HCl (pH 7.4), 1 mM
EDTA, 1 mM Na3VO4, and Complete Protease Inhibitor
Cocktail Tablets (Roche, Basel, Switzerland). The homogenate
was centrifuged at 1,0006g for 10 minutes at 4uC to remove the
nuclei. The supernatant was centrifuged again at 13,0006g for
30 minutes at 4uC. The pellet was washed extensively in the same
buffer, centrifuged as above, and the pellet (mitochondrial fraction)
was re-suspended in lysis buffer containing 150 mM NaCl,
50 mM Tris-HCl (pH 7.4), 1 mM EDTA, 1 mM Na3VO4,
Complete Protease Inhibitor Cocktail Tablets (Roche, Basel,
Switzerland), and 1% NP-40. Supernatant was further purified at
100,000 g for 30 min (4uC) and used as the cytosolic fraction.
Miscellaneous methods
Sample preparation for Western blotting, gel preparation, and
electrophoretic conditions have been described previously [8].
Western blot analyses were performed with the use of anti-
GAPDH antibody (Chemicon International, Temecula, CA), anti-
HSPB5 antibody (SPA-223, Assay Designs Inc., Ann Arbor, MI),
anti-cytochrome c antibody (BD Bioscience, CA), anti-voltage
dependent anion channel (VDAC) antibody (EMD Chemicals
Inc., Gibbstown, NJ), and anti-BCL2 antibody (SC7382, Santa
Cruz Biotechnology, Inc., Santa Cruz, CA) and anti-BAX
antibody (SC6236, Santa Cruz Biotechnology, Inc.). The band
intensity in the immunoblot was semi-quantified using Image J1.
The filter assay for the detection of the aggregates was performed
as described previously [8]. The aggregates were detected with an
anti-HSPB5 antibody. TUNEL staining was carried out using an
in-situ cell death detection kit, TMR Red (Roche, Basel,
Switzerland), following the manufacturer’s instructions as de-
scribed previously [8]. To detect anti-annexin V positive cells as a
marker of apoptotic cell death, an ApoAlert Annexin V-FITC
Apoptosis Kit was used (Takara Bio Company, Shiga, Japan),
following the manufacturer’s instructions. The number of DAPI-
labeled nuclei was counted and compared to the number of
TUNEL-positive and annexin V-positive cells [9]. Echocardiog-
raphy [8] and trichrome staining [8] were performed as described
previously.
Transgenic mice
Female mice with cardiac-specific overexpression of mutant
HSPB5 containing the R120G mutation, driven by the a-myosin
heavy chain promoter, have been described previously [8]. The
TG mice were identified by PCR analysis of genomic DNA
isolated from tail tips. The R120G TG mice used for all
experiments were backcrossed with a C57BL/6 SLC mouse more
than 10 times, and maintained on a C57BL/6 SLC background
[12] (SLC Inc., Shizuoka, Japan). Non-transgenic (NTG) litter-
mates were always used as controls for comparison. Animals were
housed in microisolator cages in a pathogen-free barrier facility.
All experimentation was performed under approved institutional
guidelines.
Experimental design and drug treatment
Nicorandil was kindly provided by Chugai Pharmaceutical Co.,
LTD (Tokyo, Japan). For the study with cardiomyocytes,
nicorandil was dissolved in medium. After 24-hr of plating the
primary isolated cardiomyocytes, they were infected with an
adenoviral vector containing HSPB5 R120G as well as HSPB5.
Nicorandil was dissolved into the culture medium 24-hr after the
Nicorandil and HSPB5 R120G Transgenic Mice
PLoS ONE | www.plosone.org 2 April 2011 | Volume 6 | Issue 4 | e18922Figure 1. Effects of nicorandil (Nico) in neonatal rat cardiomyocytes expressing HSPB5 R120G (R120G). (A) Typical pictures of Western
blot analysis. Cardiomyocytes were infected with the adenovirus vector containing the wild-type HSPB5 (HSPB5) or R120G with or without Nico
treatment. (B) Quantitative analysis of HSPB5 (n=4). Values are the x-fold increase relative to cardiomyocyte cultures infected with the adenovirus
vector containing LacZ whose values are arbitrarily set to 1. (C) Representative pictures of immunohistochemical analyses of the R120G-infected
cardiomyocytes. HSPB5 (green) was detected by the anti-HSPB5 antibody as described in the Materials and methods section. To distinguish between
the cardiomyocytes, cardiac troponin I was stained (red). (D) Typical picture of the filter assay for the detection of the aggregates. (E) Quantitative
Nicorandil and HSPB5 R120G Transgenic Mice
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blotting, cellular viability assay and immunohistochemistry were
performed. To analyze the underlying mechanism of nicorandil,
diazoxide, a specific mitoK(ATP) channel opener, 5-hydroxyde-
canoic acid (5-HD), a specific inhibitor of the mitoK(ATP)
channel, and sodium nitroprusside (SNP), a nitric oxide donor,
were dissolved in media, and the cardiomyocytes were treated
using the same protocol as for nicorandil.
For oral administration in the TG mice, nicorandil was
dissolved in tap water and water consumption was measured for
a week to adjust the dose to 15 mg/kg/day (81 mg/l of drinking
water). The effects of nicorandil on cardiac disease were examined
in R120G TG mice using two different protocols. In the first
protocol, nicorandil treatment was started from 12 weeks of age, at
which time cardiac disease is mild, in the TG mice for 4 weeks
after genotyping TG mice with tail tips. In the second protocol,
nicorandil was administered to the TG mice from 20 weeks of age,
in which marked cardiac disease such as cardiac hypertrophy and
interstitial fibrosis were observed. Western blotting, morphological
analysis, immunohistochemistry and echocardiography were
performed on the mice as described above at 16 weeks of age
and 28 weeks of age after treatment.
Statistics
Data are expressed as the mean 6 standard error. Statistical
analysis was performed using the unpaired Student’s t-test and
one-way or two-way ANOVA followed by a post hoc comparison
with Fisher’s PLSD using Statview version 5.0 software (Concepts,
Inc., Berkeley, CA). Differences between groups were considered
statistically significant at the level of p,0.05. Kaplan-Meier
Figure 2. Cytochrome c levels of mitochondrial fraction isolated from the cardiomyocytes expressing HSPB5 R120G (R120G) with or
without Nico treatment. (A) Typical pictures of Western blot analysis. Quantitative analysis of cytochrome c (B) and HSPB5 (C) in mitochondrial and
cytosolic fractions isolated from the cardiomyocytes. GAPDH was used as a loading control in the cytosolic fraction and the voltage-dependent anion
channel (VDAC) was used in mitochondrial fraction. *p,0.05, ** p,0.01, ***p,0.001 vs. the cardiomyocytes infected with LacZ (LacZ), ##p,0.01,
###p,0.001 vs. the cardiomyocytes infected with wild-type HSPB5 (HSPB5), ap,0.05 vs. cardiomyocytes infected with R120G treated with PBS.
(n=6).
doi:10.1371/journal.pone.0018922.g002
analysis of the aggregates containing the mutant R120G protein with or without Nico treatment (n=4). (F) Representative pictures of
immunohistochemical analyses in the R120G-infected cardiomyocytes. An amyloid oligomer (green) was detected by the anti-oligomer antibody as
described in the Materials and methods section. (G) Quantitative analysis of the amyloid oligomer. Amyloid oligomer levels were measured by
fluorescence intensity (n=4). (H and I) Dot blotting shows the presence of the amyloid oligomer in the recombinant R120G protein with or without
Nico treatment. (J) Protective effects of Nico on the cellular viability of the R120G infected cardiomyocytes. Cellular viability was determined by the
MTT assay. Values are the x-fold increase relative to the cardiomyocyte infected with LacZ whose values are arbitrarily set to 1 (n=6). *** p,0.001 vs.
the cardiomyocytes infected with LacZ, # p,0.05 vs. cardiomyocytes infected with R120G.
doi:10.1371/journal.pone.0018922.g001
Nicorandil and HSPB5 R120G Transgenic Mice
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version 5.0a software (GraphPad Software Inc., La Jolla, CA)
Ethics
This study was approved by the Animal Care Committee of
Iwate Medical University (Approval ID: 22-020). All experimental
procedures were performed in accordance with the Guidelines of
the Iwate Medical University Ethics Committee for Animal
Treatment and the Guidelines for Proper Conduct of Animal
Experiments by the Science Council of Japan.
Results
Effects of nicorandil on cellular toxicity induced by R120G
in neonatal rat cardiomyocytes
Effects of nicorandil on cellular toxicity induced by R120G were
evaluated in neonatal rat cardiomyocytes using an adenoviral
expression system. The adenovirus containing the wild-type
HSPB5 gene generated twice the level of HSPB5 expression in
cardiomyocytes compared to that in cardiomyocytes infected with
the adenovirus-containing LacZ gene (Figure 1A and 1B). No
differences of HSPB5 protein levels were seen among the
cardiomyocytes infected with the wild-type HSPB5-adenovirus
and the R120G-adenovirus with or without nicorandil treatment
(Figure 1A and 1B). The R120G protein induced HSPB5
containing aggregates (Figure 1C–E) as well as amyloid oligomers
(Figure 1E and F) in the cardiomyocytes, whereas no aggregates
containing HSPB5 and amyloid oligomers were detected in the
cardiomyocytes expressing the wild-type HSPB5. Levels of the
aggregates and the amyloid oligomers were unchanged by
treatment of nicorandil in the cardiomyocytes expressing R120G
(Figure 1C–G). The amyloid oligomers may represent the primary
toxic mechanism of amyloid pathogenesis, including DRM [8]. To
further examine the direct effect of nicorandil on amyloid oligomer
formation, we performed the dot blot analysis using recombinant
R120G protein. Whereas the amyloid oligomer levels of the
R120G were decreased by HSPB8, a positive control, no
significant effect on amyloid oligomer levels by nicorandil
treatment in dot blot analysis was observed (Figure 1H and I).
While no difference in levels of the aggregates and amyloid
oligomers were observed in the cardiomyocytes expressing R120G
with nicorandil treatment, reduction in cell viability was prevented
Figure 3. Western blot analysis of apoptosis related proteins, BAX and BCL2, and apoptotic cell death in the cardiomyocytes
expressing HSPB5 R120G (R120G) with or without Nico treatment. (A) Typical pictures of Western blot analysis. (B) Quantitative analysis of
BAX in mitochondrial fraction isolated from the cardiomyocytes. (C) Typical pictures of Western blot analysis. (D) Quantitative analysis of BCL2 in
mitochondrial fraction isolated from the cardiomyocytes. (E) Caspase 3 activity in the cardiomyocytes. (F) Typical pictures of annexin V-positive
cardiomyocytes. (G) Quantitative analysis of annexin V-positive cardiomyocytes. (H) Typical pictures of TUNEL-positive cardiomyocytes. (I)
Quantitative analysis of TUNEL-positive cardiomyocytes. ** p,0.01, ***p,0.001 vs. the cardiomyocytes infected with LacZ (LacZ), ##p,0.01,
###p,0.001 vs. the cardiomyocytes infected with wild-type HSPB5 (HSPB5), ap,0.05, aaap,0.001 vs. cardiomyocytes infected with R120G treated
with PBS. (n=6).
doi:10.1371/journal.pone.0018922.g003
Nicorandil and HSPB5 R120G Transgenic Mice
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These results suggest that nicorandil can maintain cellular viability
against the challenge of R120G-induced cellular toxicity without
alteration of the protein aggregate level as well as of amyloid
oligomer formation.
Release of mitochondrial cytochrome c in the
cardiomyocytes infected the adenovirus vector
containing the R120G
Recent studies suggest that nicorandil can function as a
mitoK(ATP) channel opener in the cardiomyocytes [4], which
implies that nicorandil may have a protective effect on the
mitochondria against cellular toxicity induced by the R120G in
the cardiomyocytes. In order to evaluate the mitochondrial
abnormality in the cardiomyocytes expressing R120G, the release
of the cytochrome c level from mitchondria to cytosol, whose
release can lead to induce nuclear apoptosis in addition to its role
in oxidative phosphorylation [13], was determined in the
cardiomyocytes (Figure 2A–C). Cytochrome c in the mitochon-
drial fraction was markedly attenuated by the overexpression of
R120G while a dramatic increase in cytochrome c was observed in
the cytosolic fraction (Figure 2A and B). Nicorandil treatment
inhibited the release of cytochrome c from the mitochondrial
fraction to cytosolic fraction (Figure 2A and B). In a previous
study, we found that R120G can strongly interact with
mitochondria, particularly VDAC, in the heart [9]. This result
may imply that the inhibition of HSPB5 interaction with
mitochondrial protein caused by nicorandil may explain the
reduction in cytochrome c release from mitochondria. Mitochon-
drial HSPB5 protein is increased in the cardiomyocytes expressing
R120G compared to that of the wild-type HSPB5 while cytosolic
HSPB5 was at a similar level (Figure 2A and C). No change of
HSPB5 levels was observed in either cytosolic or mitochondrial
fractions between the cardiomyocytes expressing R120G with or
without nicorandil treatment (Figure 2A and C). These results
suggest that nicorandil can inhibit the cytochrome c release from
mitochondria without alteration of HSPB5 distribution.
Inhibition of apoptotic cell death by nicorandil treatment
It is known that the release of cytochrome c as well as
subsequent apoptotic cell death is regulated by BCL2 family
members such as BAX, an apoptosis-inducing factor, and BCL2,
an anti-apoptotic factor [14]. The BCL family can form a complex
between BCL2 family members and can regulate permeabilization
of the mitochondrial outer membrane, which results in the release
of cytochrome c and activation of the apoptotic cell death pathway
[14]. Since nicorandil inhibited cytochrome c release from
mitochondria, this effect may be associated with the occurrence
of subsequent apoptotic cell death as well as the alteration of BCL
family members in the cardiomyocytes expressing R120G. The
expression of R120G induced an increase in the BAX/VDAC
ratio and a decrease in the BCL2/VDAC ratio in the
mitochondrial fraction from the cardiomyocytes, and nicorandil
treatment blocked these alterations of the BCL family (Figure 3A–
D). To examine whether nicorandil can change mRNA expression
levels of these factors, we performed quantitative RT-PCR
analysis. HSPB5 R120G increased the BAX/GAPDH ratio and
the BCL2/GAPDH ratio compared with cardiomyocytes express-
ing the wild-type HSPB5 (BAX/GAPDH: 4.360.4 fold, BCL2/
GAPDH: 1.460.2 fold; p,0.05). These changes in expression
levels of BAX and BCL2 were also observed in the cardiomyocytes
expressing R120G with nicorandil treatment compared with
cardiomyocytes expressing the wild-type HSPB5 (BAX/GAPDH:
4.060.3 fold, BCL2/GAPDH: 1.860.2 fold; p,0.05). There were
no differences of the expression levels of BAX and BCL2 between
the cardiomyocytes expressing R120G with or without nicorandil
treatment. Thus, these alterations of protein levels of BAX and
BCL2 by nicorandil treatment did not exactly track the changes
observed in mRNA expression. Concomitant with the alterations
of the BAX/VDAC and the BCL2/VDAC ratios, R120G induced
activation of caspase 3 (Figure 3E), and an increase in annexin V-
positive cardiomyocytes (Figure 3F and G) and TUNEL-positive
cardiomyocytes (Figure 3H and I). These results indicate that the
expression of R120G can activate the mitochondrial apoptotic cell
death pathway. Nicorandil treatment inhibited activation of
caspase 3 and the increases in annexin V- and the TUNEL-
positive cells in the cardiomyocytes expressing R120G (Figure 3A–
I). These results suggest that the recovery of cell viability by
nicorandil treatment can be mediated via inhibition of apoptotic
cell death.
Role of mitochondrial K(ATP) channel in cardiomyocytes
expressing R120G
Since it is known that nicorandil can act as a vasodilator by
activating sarcolemmal and the mitoK(ATP) channel and by
donating nitric oxide [15], the mechanism of the inhibitory effect
Figure 4. Cell viability in cardiomyocytes expressing R120G. (A)
Protective effects of 10 mM Nico or 100 mM diazoxide (Diazo) on the
cellular viability was inhibited by co-treatment with 500 mM5 -
hydroxydecanoate (5HD). (B) No detectable effect on the cellular
viability was seen by treatment with 10 mM sodium nitroprusside (SNP).
Values are the x-fold increase relative to the cardiomyocyte infected
with the LacZ whose values are arbitrarily set to 1. *** p,0.001, vs. the
cardiomyocytes infected with LacZ (LacZ), ### p,0.001, vs. the
cardiomyocytes infected with wild-type HSPB5 (HSPB5), aaa p,0.001 vs.
cardiomyocytes infected with R120G treated with PBS, and bbb
p,0.001 vs. cardiomyocytes infected with R120G treated with 10 mM
Nico or 100 mM Diazo (n=6).
doi:10.1371/journal.pone.0018922.g004
Nicorandil and HSPB5 R120G Transgenic Mice
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cardiomyocytes. As described above, nicorandil prevented the
reduction in cell viability induced by R120G (Figure 4A). Similar
to nicorandil, diazoxide, a specific mitoK(ATP) channel opener,
also inhibited the R120G-induced cell injury (Figure 4A). The
protective effect of nicorandil was completely blocked by treatment
with 5-HD, a specific mitoK(ATP) channel blocker (Figure 4A). In
contrast to diazoxide, no protective effect was seen via treatment
with SNP, a nitric oxide donor (Figure 4B). These results suggest
that the mitoK(ATP) channel opening by nicorandil plays an
important role in cellular protection in cardiomyocytes expressing
R120G. Thus, nicorandil, the mitoK(ATP) channel opener, may
protect against mitochondrial abnormalities, cellular toxicity and
subsequent cell death, including apoptosis, in DRM.
Effect of nicorandil in R120G TG mice at a relatively early
stage
Our in-vitro study indicates that nicorandil can protect against
mitochondrial abnormalities, cellular toxicity and subsequent cell
death, including apoptosis, in DRM. To extend the results of the
in-vitro study, we analyzed the effect of nicorandil in R120G TG
mice in vivo. At first, nicorandil treatment was started from 12
weeks of age, in which cardiac disease including mitochondrial
injury is mild, in the R120G TG mice for 4 weeks (Figure 5A).
Systolic blood pressure, heart rate in a conscious state, and heart
weight/body weight ratio are shown in Table 1. No differences in
systolic blood pressure or heart rates were seen among NTG mice
or R120G TG mice with or without nicorandil treatment (Table 1).
These results imply that changes in blood pressure caused by
nicorandil treatment under present experimental conditions are
unlikely in the R120G TG mice. We also determined cardiac
function via echocardiography in the R120G TG mice. No
differences in cardiac function, such as measured fractional
shortening, were observed among the NTG or R120G TG mice
with or without nicorandil treatment at 16 weeks of age
(Figure 5G). An increased level of HSPB5 was observed in the
cardiac ventricle of the R120G TG mice compared with that in
NTG mice (Figure 5B and C). No differences in the cardiac
HSPB5 level between the R120G TG mice with or without
nicorandil treatment were observed (Figure 5B and C). Immuno-
histochemical analysis showed that small aggregates containing
HSPB5 were present in the R120G TG mice with or without
nicorandil treatment, and aggregate level was unaffected by
nicorandil treatment (Figure 5D–F). The heart weight/body
weight ratio of the R120G TG mice was higher than that of
NTG mice (Table 1). This increased weight ratio was unchanged
by nicorandil treatment (Table 1). Similar to the heart weight/
body weight ratio, ventricular ANF levels, a typical hypertrophic
marker [16] (Figure 5H and I) and perivascular fibrosis (Figure 5J)
were unchanged by nicorandil treatment, whereas obvious ANF
induction and typical perivascular fibrosis was observed in the
R120G TG mice compared to in the NTG mice. At the same
time, no release of cytochrome c from the mitochondrial fraction
was detected in the ventricle from the R120G TG mice (Figure 5K
and L). Thus, there results imply that no effective recovery of
cardiac disease by nicorandil treatment is exerted in the R120G at
16 weeks of age when the cardiac disease, including release of
mitochondrial cytochrome c, is relatively mild.
Anti-apoptotic effect of nicorandil in HSPB5 R120G TG
mice at a late stage
Nicorandil can inhibit the release of cytochrome c, ANF
induction and concomitant cell death in the cardiomyocytes
expressing the mutant HSPB5 as described above. In an in-vivo
DRM model, no beneficial effect of nicorandil treatment was
detected when cardiac disease, and mitochondrial abnormalities
were relatively mild. As a next step, we examined the effects of
nicorandil on DRM disease at a late stage, in which mitochondrial
abnormalities have occurred (Figure 6A). Nicorandil was admin-
istered to the TG mice from 20 weeks of age (Figure 6A). At that
time, cardiac disease, as manifested by reduced fractional
shortening (Figure 6B), cardiac hypertrophy (Figure 6C), intracel-
lular aggregates (Figure 6D and E), amyloid oligomers (Figure 6D
and F) and interstitial fibrosis (Figure 6G) were observed
(Figure 6B–G). Further progression of these pathologies were seen
in the mutant TG mice at 28 weeks of age (Figure 6). Nicorandil
Table 1. Heart weight and blood pressure.
NTG HSPB5 R120G TG HSPB5 R120G TG+Nico
Systolic blood pressure (mmHg) 106629 8 639 9 63
Heart rates (beats/min) 679614 646666 3 5 610
Body weight (g) 25622 4 622 5 62
Heart weight/body weight ratio (mg/g) 4.360.2 5.860.2*** 5.760.1
Values are mean6SEM; TG: transgenic, NTG: non-transgenic; n=6–8 nico, nicorandil.
***p,0.001 vs. NTG)mice.
doi:10.1371/journal.pone.0018922.t001
Figure 5. Effect of Nico (81 mg/l of drinking water) on cardiac disease at a relatively early stage in the HSPB5 R120G (R120G) TG
mice. (A) Protocol was shown. Nico was administered via drinking water from 12 weeks for a total of 4 weeks in the R120G TG mice. (B) Typical
pictures of Western blot analysis. (C) Quantitative analysis of HSPB5. Values are the x-fold increase relative to values in non-transgenic (NTG) mouse
hearts whose values are arbitrarily set to 1. (D) Representative pictures of the immunohistochemistry are shown. (E) Typical picture of the filter assay
for the detection of the aggregates containing HSPB5 proteins. (F) Quantitative analysis of the aggregates containing mutant R120G protein. (G)
Fractional shortening assessed by the echocardiogram. Cardiac functional measurements were made at 16 weeks (n=8 mice). (H) Typical pictures of
Western blot analysis for ANF. (I) Quantitative analysis of ANF in the hearts in the R120G TG mice. (J) Masson’s trichrome staining. (K) Cytochrome c
levels of mitochondrial fraction isolated from the hearts from the R120G TG mice with or without Nico treatment. Typical pictures of Western blot
analysis. Quantitative analysis of cytochrome c. GAPDH was used as a loading control in the cytosolic fraction and the voltage-dependent anion
channel (VDAC) was used in the mitochondrial fraction. (L) Quantitative analysis of cytochrome c in mitochondrial and cytosolic fractions isolated
from the hearts in the R120G TG mice. *p,0.05, ***p,0.001, vs. the NTG, #p,0.05 vs. the R120G TG mice (n=6–8).
doi:10.1371/journal.pone.0018922.g005
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PLoS ONE | www.plosone.org 8 April 2011 | Volume 6 | Issue 4 | e18922Figure 6. Effect of Nico (81 mg/l of drinking water) on cardiac disease at late stage in the HSPB5 R120G (R120G) TG mice. (A) Protocol
was shown. Nico was administered via drinking water from 20 weeks of age in the R120G TG mice. (B) Fractional shortening assessed by the
echocardiogram. Cardiac functional measurements were made at 28 weeks (n=6–10 mice). (C) The ratios of heart weight/body weight. (n=6–10). (D)
Representative pictures of the immunohistochemistry are shown. The aggregates containing the mutant R120G protein (upper panel green) and
amyloid oligomer (lower panel green) were observed in the R120G TG mice. To distinguish between the cardiomyocytes, cardiac troponin I was
stained (upper panel red) (E and F) Quantitative analysis of the aggregates containing the mutant HSPB5 R120G protein (E) and amyloid oligomer (F).
(n=4). (G) Masson’s trichrome stain in the R120G TG mouse heart with or without Nico treatment. * p,0.05, *** p,0.001 vs. non-transgenic (NTG)
mice; # p,0.05, ### p,0.001 vs. R120G TG mice.
doi:10.1371/journal.pone.0018922.g006
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obvious effects on cardiac hypertrophy, level of the aggregates,
level of the amyloid oligomers, or presence of fibrosis being
detected (Figure 6B–G). However, nicorandil treatment did have
beneficial effects, including, increased survival (Figure 7A),
decreased ANF induction (Figure 7B and C), and decreases in
TUNEL-positive cardiomyocytes (Figure 7D). Mitochondrial
cytochrome c was released in the ventricle from R120G TG mice
at this age (Figure 7E and F), and nicorandil treatment blocked this
as well (Figure 7E and F). Concomitant with a reduction of
cytochrome c being released from the mitochondria, a marked
decrease in BCL2 as well as a marked increase in BAX were
observed in the R120G TG mice (Figure 8A–C), and nicorandil
treatment inhibited these alterations in R120G TG ventricles.
These data indicate that nicorandil treatment appeared to reduce
mitochondrial impairment, such as release of cytochrome c, and
inhibit activation of the apoptotic pathway, such as decrease in
BCL2 and increase in BAX, and inhibit the subsequent induction
of apoptotic cell death, thereby prolonging the survival in R120G
TG mice. Thus, nicorandil, a mitoK(ATP) channel opener, may
prolong survival in R120G TG mice by protecting against
mitochondrial impairments and inhibiting apoptotic cell death.
Discussion
We have demonstrated that progressive mitochondrial abnor-
malities and apoptotic cell death occur in the hearts of R120G TG
mice in previous studies [8,9]. Although it is known that these
abnormalities (such as mitochondrial dysfunction and apoptotic
cell death) are probably associated with disease of the DRM, the
role of mitochondrial dysfunction and apoptotic cell death in
disease progression remains uncertain. In the present study, we
analyzed the effect of nicorandil, a mitoK(ATP) channel opener,
on disease progression such as mitochondrial injury and the
Figure 7. Effect of Nico (81 mg/l of drinking water) on survival rate and biochemical parameters at the late stage in the HSPB5
R120G (R120G) TG mice. (A) Survival curves. Nico effectively attenuated premature death in R120G TG mice. (B) Typical pictures of Western blot
analysis for ANF. (C) Quantitative analysis of ANF in the hearts in the R120G TG mice. (D) Quantitative analysis of TUNEL-positive cardiomyocytes. (E)
Typical pictures of Western blot analysis. (F) Quantitative analysis of HSPB5 and. Values are the x-fold increase relative to values in non-transgenic
(NTG) mouse hearts whose values are arbitrarily set to 1. (D) Representative pictures of the immunohistochemistry are shown. The aggregates
containing the mutant R120G protein are observed in R120G TG mice with or without Nico treatment. (E) Cytochrome c levels of mitochondrial
fraction isolated from the R120G TG mouse heart with or without Nico treatment. (F) Typical pictures of Western blot analysis. Quantitative analysis of
cytochrome c (F upper colomun) and HSPB5 (F lower column) in mitochondrial and cytosolic fraction isolated from the R120G TG mice. GAPDH was
used as a loading control in the cytosolic fraction and voltage-dependent anion channel (VDAC) was used in the mitochondrial fraction. ***p,0.001
vs. non-transgenic (NTG) mice; # p,0.05, ### p,0.001 vs. R120G TG mice (survival rate: n=19–20, and other experiments: n=4).
doi:10.1371/journal.pone.0018922.g007
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survival rate in the desmin-related cardiomyopathy. This must be
studied carefully, because nicorandil affects the salcoremmal
K(ATP) channel as well as guanylate cyclase as a NO donor in
vessels [1]. As such, we employed two different experimental
protocols: treatment at a relatively early stage and treatment at a
relatively late stage. In the early stage, when relatively mild
mitochondrial abnormalities are observed in the cardiomyocytes,
no beneficial effect on cardiac hypertrophy, fibrosis, or ANF
induction was detected by nicorandil treatment. In contrast,
nicorandil treatment prolonged survival, reduced mitochondrial
injury, and inhibited apoptotic cell death in R120G TG mice at a
relatively late stage when we commenced nicorandil treatment at
20 weeks of age, when mitochondrial abnormalities are observed
in the cardiomyocytes. In this experiment, we commenced
nicorandil treatment at 20 weeks of age, when no release of
cytochrome c from mitochondria had been observed although
reduced cardiac function, cardiac hypertrophy, and cardiac
fibrosis had already been observed in R120G TG mice. Although
it is difficult to rule out other possibilities of protective actions such
as focal vascular protection by nitric oxide and cellular protection
via salcoremmal K(ATP) channel opening by nicorandil treat-
ment, our findings imply that nicorandil treatment may be
beneficial for the DRM via myocardial mitochondria protection
and the inhibition of apoptotic cell death in the cardiomyocytes.
In our previous study, we found that R120G, which can cause
DRM, led to increased perinuclear aggresome formations that
contain amyloid oligomers, depressed cardiac function, and
premature lethality [8]. Since it is hypothesized that amyloid
oligomers can permeabilize cellular membranes and lipid bilayers,
which may represent the primary toxic mechanism of amyloid
pathogenesis [17], cellular toxicity induced by the amyloid
oligomers is associated with mitochondrial function as well as
induction of apoptotic cell death by cytochrome c release from
mitochondria [8,9]. In the present study, nicorandil treatment
inhibited the release of cytochrome c from mitochondria,
activation of caspase 3, and the occurrence of apoptotic cell death
in the cardiomyocytes as well as in-vivo TG mouse hearts, while the
levels of amyloid oligomers as well as of the aggregates were
unchanged in both the cardiomyocytes and TG mice. These
results indicate that nicorandil can display cardioprotective effects
without modification of the mutant protein accumulation.
Nicorandil has been reported to display cardioprotective charac-
teristics including anti-apoptotic cell death behavior through
activation of mitoK(ATP) channels [4]. Our results also showed
that nicorandil as well as diazoxide, another mitoK(ATP) channel
opener, decreased the cell toxicity induced by R120G, and 5-HD,
a K(ATP) channel antagonist, blocked these protective effects by
nicorandil and diazoxide in cardiomyocytes. Furthermore, nicor-
andil alone displayed cardioprotective effects in the R120G TG
mice under relatively severe conditions, in which mitochondrial
abnormalities such as cytochrome c leakiness occurred in the
heart, while no beneficial effects were detected in this model under
mild conditions. These results may imply that the opening of a
K(ATP) channel in mitochondria can be cardioprotective against
toxicity via mutant HSPB5, such as protein aggregates, and
amyloid oligomers or can inhibit activation of the signaling
pathway of apoptosis that is stimulated by the mutant protein
accumulation in the cardiomyocytes. Thus, mitoK(ATP) channel
opening may be beneficial for inhibition of disease progression via
mitochondrial injury and apoptotic cell death in DRM, particu-
larly when cardiac disease is severe.
The underlying mechanism(s) of protective action via opening
the mitoK(ATP) channels through nicorandil treatment on cardiac
disease in the DRM is unclear. It is known that the opening of
mitoK(ATP) channels can be protective during ischemia-reperfu-
sion. MitoK(ATP) channels were also proposed to be the end-
effecter of IPC, a mechanism by which an exposure to brief
periods of ischemia may provide protection against subsequent
sustained ischemia/reperfusion injury [18,19]. However, the
mechanisms by which mitoK(ATP) channels exert their cardio-
protective effects were also poorly understood. A mitoK(ATP)
channel opener such as diazoxide led to a decrease in the inner
membrane potential (DYm) via modulation of Ca2+ influx and
efflux through a ruthenium red-sensitive Ca2+ uniporter and a
cyclosporin A-sensitive mitochondrial permeability transition pore,
specific, voltage-dependent, nonselective high-conductance chan-
nels [20,21]. Another study demonstrated that reduction in
mitochondrial Ca2+ by diazoxide correlated with the post-
ischemic recovery of the contractility in isolated, perfused hearts
[22]. Furthermore, a significant increase in mitochondrial volume
was observed by opening the mitoK(ATP) channel; this effect may
Figure 8. Western blot analysis of apoptosis-related proteins,
BAX and BCL2, and apoptotic cell death in HSPB5 R120G
(R120G) TG mice with or without Nico treatment. (A) Typical
pictures of Western blot analysis. (B and C) Quantitative analysis of BAX
(B) and BCL2 (C) in mitochondrial fraction isolated from the TG mouse
hearts. * p,0.05, **p,0.01 vs. non-transgenic (NTG) mice; # p,0.05 vs.
R120G TG mice (n=4).
doi:10.1371/journal.pone.0018922.g008
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the architecture of the intermembrane space with the consequent
slowing of ATP hydrolysis [23]. It is suggested that the generation
of reactive oxygen species leading to apoptotic cell death under
ischemic/reperfused conditions is regulated by mitoK(ATP)
channels in hearts [24,25]. Because most of the previous findings
related to the mitoK(ATP) channel were obtained using the
isolated mitochondria, primary-cultured cardiomyocytes, and
isolated, perfused hearts as acute effects, it is uncertain if the
similar mechanism(s) of cardioprotection occur in chronic disease
such as DRM by long-term treatment with a mitoK(ATP) channel
opener. Since IONA study suggested that long-term treatment
with nicorandil exerts cardioprtective effects via mitoK(ATP)
channel opening, our findings concerning effects of nicorandil in
DRM may be also exerted via mitoK(ATP) channel opening [1,3].
Further study is needed to analyze the mechanism(s) of nicorandil
in cardiac disease in the DRM.
Nicorandil treatment prevented the increase in BAX [26], an
apoptotic inducible factor, and the decrease in BCL2, an anti-
apoptosis factor [27], in cultured cardiomyocytes expressing
mutant HSPB5 well as in the mutant TG mouse hearts. Apoptosis,
a distinct type of cell death, is governed by a number of regulating
genes from the BCL2 family, such as BCL2, BAX, BAK and BCL-
X [28,29]. The balance between expression of BCL2 and BAX
plays an important role in the pathway of apoptotic and necrotic
cell death [4,28,30]. These previous studies and our results suggest
that the protein levels of apoptotic-related factors such as BCL2
and BAX may play a vital role in the initiation and development of
cardiac disease in DRM. After administration of nicorandil, the
protein level of BAX was attenuated while BCL2 levels were
elevated in mitochondria, resulting in an elevated ratio of BCL2/
BAX in comparison with those in untreated TG mice. Interest-
ingly, a recent study showed that sustained BCL2 overexpression
in R120G hearts prolonged these mice’s survival [31]. This was
associated with decreased mitochondrial abnormalities, restoration
of cardiac function and attenuation of apoptosis [31]. The results
of this study are quite similar to those in our present study, which
indicates that nicorandil may prevent the pathogenesis and
development of DRM via regulation of protein levels of the
BCL family members such as BCL2 and BAX.
Although the protein levels of BCL2 and BAX were altered in
the cardiomyocytes by the mutant HSPB5 and these alterations
were blocked by nicorandil treatment in vitro and in vivo, these
protein levels were independent of the mRNA expression in the
hearts. Additionally, no correlation between the gene expression
and the protein in BCL family members were observed in other
studies [30], whereas direct correlation was seen in hypoxia-
induced apoptosis in cardiomyocytes via nicorandil treatment [4].
The exact mechanism(s) causing the different results related to the
BCL family between previous studies and the present study, and
the divergent regulation between protein level and mRNA level in
the BCL family in the hearts have not been fully clarified. It is
known that BCL2 protein is cleaved by caspase, and a positive
feedback between BCL2 and caspases is present [32]. Since it is
possible that nicorandil contributes to the maintenance of the
mitochondrial membrane potential by opening of mitoK(ATP)
channels, mitochondrial membrane potential may play a role in
turnover of BCL family members [28].
In summary, our results in the present study clearly indicate that
treatment with nicorandil, the mitoK(ATP) channel opener,
appeared to reduce mitochondrial impairment and apoptotic cell
death and prolonged survival in the R120G TG mice. Nicorandil
can inhibit the alteration of BCL2 and BAX in mitochondria in
hearts from the R120G TG mice and can suppresses the
mitochondrial death pathway through opening of the mitoK(ATP)
channel, which may be involved in it’s protective effect on DRM.
Use of a mitoK(ATP) channel opener such as nicorandil may
represent a new therapeutic strategy for patients with DRM.
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